Bayer sues Teva and Barr over advertising

Published: 16-Jun-2010
Packaging Patient Experience

Teva’s generic oral contraceptive Gianvi’s label makes false claims


Bayer Schering Pharma AG and Bayer HealthCare Pharmaceuticals Inc. have sued Teva Pharmaceuticals USA, Inc., Barr Pharmaceuticals LLC, and Barr Laboratories, Inc. in the Northern District of Illinois (Chicago) for false advertising and patent infringement in connection with Teva’s generic oral contraceptive, Gianvi. Teva’s product is sold as a generic version of Bayer HealthCare’s leading oral contraceptive YAZ.

YAZ tablets contain an estrogen (17α-ethinylestradiol) stabilised by β-cyclodextrin (or ‘betadex’) as a ‘clathrate’ (a protective molecular cage). Using betadex as a clathrate improves stability and prolongs shelf life of the product.

Bayer believes Teva is offering for sale its Gianvi product with Physician Prescribing Information that falsely claims that Gianvi’s ethinyl estradiol is ‘stabilised by betadex as a clathrate’. Based on testing of tablets now in the US market, Bayer believes that Teva’s Gianvi product does not in fact contain ethinyl estradiol stabilised by betadex as a clathrate.

Bayer intends to seek a temporary restraining order and a preliminary injunction to stop Teva from making false claims about its Gianvi product and from infringing Bayer Schering’s U.S. Patent 5,798,338, which covers offers to sell a drug with an ethinylestradiol that is stabilised by betadex as a clathrate. Bayer also asks that Teva take action in the US market to correct any erroneous impression persons may have derived concerning the nature, characteristics or qualities of Gianvi.

  • Companies:
  • Teva
  • Bayer
See more

You may also like

Packaging

Bayer joins the Blister Pack Collective to reduce single-use plastics in tablet packs

Read more
PA Consulting (PA), the company bringing ingenuity to life, and PulPac, the Swedish R&D and IP company behind Dry Molded Fiber, are pleased to announce the Consumer Health division of Bayer has joined the Blister Pack Collective

Trending Articles

  1. Dual-chamber packaging systems as a simplification factor in the supply chain Dual-chamber packaging solutions could represent a new frontier also to package parenteral drugs, simplifying the supply chain through reconstitution, potentially making logistics more flexible and efficient, says Cecilia Bassi, Product Manager at Bormioli Pharma
  2. AstraZeneca to stop production of Pulmicort pMDI Agreements with SkyePharma expected to be terminated
  3. Bormioli Pharma to digitise package leaflets using augmented reality The project is part of the Bormioli Pharma Invents innovation programme, which aims to provide concrete answers to some of the most important challenges in the pharmaceutical packaging sector.
  4. Navigating regulatory challenges in pharmaceutical packaging: lessons from the past and strategies for the future To safeguard drug efficacy, maintain strict quality standards and ensure patient safety, pharmaceutical packaging is subject to a wide range of regulations around the world, reports Kun Shing Chan, Director of QA at Tjoapack
  5. Almac Group The Almac Group is an established contract development and manufacturing organisation which provides an extensive range of integrated services to the pharmaceutical and biotech sectors globally

Upcoming event

CPhI India

26–28 November 2024 | Online Conference & Networking | Delhi, India See all

You may also like

Packaging

Bayer joins the Blister Pack Collective to reduce single-use plastics in tablet packs

PA Consulting (PA), the company bringing ingenuity to life, and PulPac, the Swedish R&D and IP company behind Dry Molded Fiber, are pleased to announce the Consumer Health division of Bayer has joined the Blister Pack Collective
Manufacturing

Teva Pharmaceuticals gives a look into each step of sterile medicine production

Teva Pharmaceuticals has released a video showing production steps at a site that manufactures 480 million doses a year
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

US-India relations stall over pharma IP squabble

IP protection for international pharmaceutical companies in India remains an unresolved issue, as India battles for affordable medicines and the US argues that better patent protection must be forthcoming. The potential of this huge market hangs in the balance as discussions continue
Research & Development

Cellectis gives Bayer access to homologous recombination patents

<p>Cellectis, a French genome engineering company, and Bayer Healthcare have signed an agreement under which Bayer will have access to Cellectis&quot; WO9011354 patent family covering homologous recombination aimed at introducing new features into the genome. </p>
Packaging

Bayer Healthcare chooses packaging seal that offers comfort and security

Bayer Healthcare had exacting requirements for Schreiner MediPharm and Schreiner ProSecure
Packaging

Dual-chamber packaging systems as a simplification factor in the supply chain

Dual-chamber packaging solutions could represent a new frontier also to package parenteral drugs, simplifying the supply chain through reconstitution, potentially making logistics more flexible and efficient, says Cecilia Bassi, Product Manager at Bormioli Pharma
Packaging

Bormioli Pharma to digitise package leaflets using augmented reality

The project is part of the Bormioli Pharma Invents innovation programme, which aims to provide concrete answers to some of the most important challenges in the pharmaceutical packaging sector.
Subscribe now